|
NP CHRONICLES Clinical Education for NP
Students & New Grads |
The
New Era of Obstructive Sleep Apnea Care
From
Underdiagnosis to an Evolving Treatment Paradigm
Why This
Matters in Primary Care
An estimated 83.7 million U.S. adults
have obstructive sleep apnea (OSA) — and roughly 80% of clinically
significant cases go undiagnosed. That gap matters, because untreated
moderate-to-severe OSA is tied to nearly double the risk of stroke, atrial
fibrillation, heart failure, and coronary disease, plus impaired glucose
metabolism, cognitive decline, depression, and — over 14 years of follow-up —
up to a fivefold increase in cardiovascular mortality in patients not using
CPAP.
The problem isn't just that OSA is common.
It's that most primary care visits are still screening for the “classic”
patient — a sleepy, snoring, middle-aged man with obesity — while a large share
of real-world OSA presents very differently.
|
✦ CLINICAL BOTTOM LINE OSA is a major, modifiable driver of cardiometabolic
and neurocognitive disease, but the majority of cases are missed because
clinicians are screening for one phenotype in a condition with many. |
The
Pathophysiology Behind the Heterogeneity
OSA results from a sleep-induced imbalance
between upper airway load (soft palate, tongue fat, hyoid position,
retrognathia) and airway dilator muscle tone (hypoglossal motor output,
noradrenergic/serotonergic drive). When load exceeds tone, the airway narrows
or collapses, triggering intermittent hypoxia, arousal, and sleep fragmentation
— which drive oxidative stress, sympathetic activation, and systemic
inflammation.
Beyond anatomy, four non-anatomical endotypes
are now recognized as contributing to OSA in most patients:
•
Low arousal
threshold — waking too easily to
sustain stable breathing
•
Unstable
ventilatory control —
exaggerated breathing responses to small CO₂ changes
•
Upper airway
collapsibility — anatomic
susceptibility to obstruction
•
Poor
pharyngeal muscle responsiveness
— inadequate dilator muscle activation
This endotype mix helps explain why OSA
doesn't look the same in every patient — and why symptom clusters
(insomnia-predominant, fatigue-without-sleepiness, mood/cognitive,
morning/nocturnal, or minimally symptomatic) are so common outside the
“classic” presentation.
Who Gets Missed
•
Women, especially peri- and post-menopausal, often
present with insomnia, fatigue, depressive symptoms, morning headache, and
nightmares rather than witnessed apneas
•
Older adults more often report insomnia, nocturia,
cognitive complaints, or falls than sleepiness
•
Young,
non-obese patients can have
severe OSA driven by craniofacial anatomy (retrognathia, high-arched palate,
macroglossia) with atypical symptoms like bruxism and headache
|
⚠ NUANCE TO FLAG FOR LEARNERS Current OSA phenotyping (older adult, female,
nonanatomic, REM-related, supine-predominant, symptom-based clusters) does
not yet reliably predict clinical presentation or cardiometabolic risk —
evidence is strongest for endotype and symptomatic (EDS/insomnia)
classification, and weaker for genomic/genetic correlates. Don't over-anchor
on any single phenotype label; use it to broaden your differential, not
narrow your screening. |
Case From
Practice: Kim, 56
|
CASE FROM PRACTICE Chief complaint: “I’m exhausted all the time, and I stay up all night.” Kim is 56, BMI 29 kg/m², postmenopausal since age 52.
Over the past two years she's developed insomnia, frequent nightmares,
trouble concentrating, and worsening mood, plus morning headaches. Her
history includes resistant hypertension and depression. She's unsure if she
snores but wakes 2–4 times nightly, feels unrefreshed, and denies obvious
daytime sleep episodes. Exam is notable for Mallampati Class III, mild
retrognathia, a crowded posterior oropharynx, chronic nasal congestion, and a
history of jaw clenching/bruxism. What makes Kim easy to miss: She's female, postmenopausal,
non-obese, and reports insomnia rather than sleepiness — none of which fit
the classic OSA script. But her symptom cluster (insomnia, fatigue, cognitive
complaints, mood changes, morning headache), resistant hypertension, and
airway exam findings are exactly the picture non-anatomic endotypes and
craniofacial risk factors predict. Next steps for a patient like Kim: |
•
Take a full
sleep history — sleep pattern, nighttime awakenings, snoring, witnessed
gasping/apneas, and daytime impact
•
Ask about
nasal obstruction, chronic congestion, or prior ENT surgery
•
Examine the
airway (Mallampati class, tonsil size, retrognathia) and calculate BMI/neck
circumference
•
Use a
validated screening tool to support — not replace — clinical judgment, and
refer for sleep testing even if the score isn't high, given her risk factors
and resistant hypertension
Screening
& Diagnosis in Primary Care
Validated Screening Tools
|
Tool |
Description |
Sens. |
Spec. |
|
Berlin Questionnaire |
11 items across snoring/apneas,
fatigue/sleepiness, obesity/hypertension |
77% |
44% |
|
STOP-Bang |
8 items: snoring, tiredness,
observed apnea, pressure, BMI, age, neck size, sex |
90% |
36% |
|
Epworth Sleepiness Scale (ESS) |
Self-administered sleepiness
tendency across 8 situations |
47% |
62% |
No single tool is diagnostic, and none were
designed to capture non-classical presentations — they're a starting point for
risk stratification, not a gate that determines who gets tested.
Who Should Be Screened Annually
(AASM)
Per the American Academy of Sleep Medicine's
OSA Screening Health Advisory, annual screening is recommended for
adults with:
•
Heart failure
•
Elevated blood pressure
•
Atrial fibrillation
•
Resistant hypertension
•
Type 2 diabetes
•
Stroke
Also screen patients with BMI ≥30 kg/m²,
nocturnal dysrhythmias, pulmonary hypertension, coronary artery disease, or
those preparing for bariatric surgery.
Confirming the Diagnosis
Per AASM criteria, OSA is diagnosed when
either:
•
(A) One or more of: sleepiness/nonrestorative
sleep/fatigue/insomnia, waking with gasping/choking, bed-partner-reported
snoring or breathing interruptions, or a diagnosis of hypertension, mood
disorder, cognitive dysfunction, CAD, stroke, CHF, AFib, or T2D AND (B) ≥5
predominantly obstructive respiratory events/hour on PSG or HSAT
•
OR (C) ≥15 predominantly obstructive respiratory
events/hour on PSG or HSAT alone
PSG (in-lab polysomnography) remains the gold standard, particularly for
patients with significant comorbidities or suspected non-OSA sleep disorders,
and should be strongly considered when HSAT is inconclusive in a high
pretest-probability patient. HSAT (home sleep apnea testing) is a
validated, more convenient alternative for uncomplicated, high-probability OSA,
but it hasn't been adequately validated in all populations, doesn't record
actual sleep or include ECG, and may underestimate severity.
Severity is classified by AHI (apneas +
hypopneas per hour of sleep): mild ≥5, moderate ≥15, severe ≥30 events/hour.
|
⚠ NUANCE TO FLAG FOR LEARNERS AHI counts events but doesn't capture how deep or how
long desaturations last. Two patients can share an AHI of 30 and have very
different hypoxic burden — and hypoxic burden may better reflect cumulative
oxygen stress and downstream cardiometabolic risk than AHI alone. This is an
evolving research metric, not yet a routine clinical reporting standard, but
worth knowing as terminology you'll increasingly encounter. |
|
✦ CLINICAL BOTTOM LINE ~80% of patients with OSA have comorbid cardiovascular
or metabolic disease, and PCPs are uniquely positioned to catch this during
routine chronic-disease visits — annual screening in high-risk groups, paired
with a low threshold for testing in atypical presentations, is where primary
care moves the needle. |
The
Treatment Paradigm Is Expanding
Treatment should be individualized to
severity, symptoms, comorbidities, and patient preference, with early
reassessment of adherence and efficacy.
Foundational and Device-Based
Options
•
CPAP remains first-line for most adults, especially
severe OSA — CPAP use ≥4 hours/night is associated with a 57% lower risk of
major adverse cardiovascular events. Adherence drops over time (from ~77% at
year 1 to ~53% by year 3), driven by nasal congestion, dryness, mask
discomfort, claustrophobia, and inconvenience.
•
Mandibular
advancement devices (MADs) advance
the lower jaw and are recommended for patients who prefer them or can't
tolerate CPAP — less efficacious than CPAP but generally better tolerated.
•
Surgery (maxillomandibular advancement, UPPP, and
others) is considered for patients unable or unwilling to use CPAP; MMA shows
the largest AHI reductions in observational data (~87%), though evidence
quality across surgical options is generally low.
•
Hypoglossal
nerve stimulation activates the
genioglossus during inspiration to advance the tongue and reduce collapse in
selected CPAP-intolerant patients.
•
Weight loss
and positional therapy are
important adjuncts — 10% weight loss can improve OSA, 30% yields the best AHI
reductions, and non-supine positioning can reduce AHI by roughly 7.4
events/hour.
Emerging Pharmacotherapy — a
Real Shift in the Paradigm
•
Tirzepatide
(Zepbound) was approved
for adults with obesity and moderate-to-severe OSA based on the SURMOUNT-OSA
phase 3 program: AHI reductions of roughly 20–24 events/hour more than placebo,
~16–17% placebo-adjusted weight loss, and improvements in hypoxic burden,
hsCRP, and systolic blood pressure. GI adverse effects (diarrhea, nausea,
vomiting, constipation) were common but mostly mild-to-moderate. Other
incretin-based agents (amycretin/zenagamtide, bofanglutide) are in phase 3 OSA
trials.
•
AD109
(aroxybutynin/atomoxetine) is a
once-nightly, fixed-dose oral combination under FDA review. Atomoxetine (a
selective norepinephrine reuptake inhibitor) increases noradrenergic drive to
the hypoglossal motor neurons; aroxybutynin (an antimuscarinic) blocks
acetylcholine-mediated suppression of hypoglossal output — together increasing
upper airway muscle tone. In the SynAIRgy phase 3 trial (n=646, adults who
refused or couldn't tolerate CPAP), AD109 produced a 44% AHI reduction from
baseline vs. 18% with placebo at 26 weeks, and a substantially larger reduction
in hypoxic burden. Common adverse events were dry mouth, nausea, insomnia, and
urinary hesitation.
These agents target the pathophysiology
directly — pharyngeal dilator muscle tone, airway collapsibility via weight
loss, and respiratory control stability — rather than mechanically bypassing
the anatomy, which is a genuinely new direction for a condition long defined by
devices and surgery.
Board Prep:
Quick-Hit Facts
•
OSA
prevalence in U.S. adults: 83.7
million; ~80% of clinically significant OSA is undiagnosed
•
AASM annual
screening acronym for
high-risk comorbidities: H-E-A-R-T-S (heart failure, elevated BP, AFib,
resistant HTN, T2D, stroke)
•
Diagnostic
criteria: (A + B) or (C alone) —
symptoms/comorbidity + AHI ≥5, or AHI ≥15 regardless of symptoms
•
Severity
cutoffs: mild ≥5, moderate ≥15,
severe ≥30 events/hour
•
PSG = gold standard; HSAT = validated
alternative for uncomplicated, high pretest-probability patients only
•
First-line
therapy for severe OSA: CPAP;
consider MAD when CPAP is not tolerated/preferred
•
CPAP use ≥4
hrs/night → 57% lower MACE risk
•
Newest
FDA-approved pharmacotherapy:
tirzepatide (obesity + moderate-to-severe OSA, per SURMOUNT-OSA)
•
AD109 (aroxybutynin/atomoxetine) mechanism:
antimuscarinic + noradrenergic reuptake inhibition → increased hypoglossal
muscle tone; currently under FDA review
Key
Takeaways
1.
OSA is common
and underdiagnosed (~80% of cases), and untreated disease drives
cardiometabolic, neurocognitive, quality-of-life, and safety harm.
2.
Non-anatomical
endotypes explain much of OSA's clinical heterogeneity — don't rule it out
because the presentation isn't “classic.”
3.
Systematic
screening and diagnostic testing beyond classic symptoms and AHI are needed to
catch atypical cases.
4.
Treatment is
expanding well beyond CPAP — oral appliances, surgery, lifestyle change, and
new pharmacotherapies (tirzepatide, AD109) are reshaping the OSA care pathway.
References
1. Sönmez I et al. Respir Med.
2025;248:108348.
2. Boers E et al. Lancet Respir
Med. 2025.
3. Veasey SC et al. N Engl J
Med. 2019;380(15):1442-1449.
4. Iannella G et al. Diagnostics
(Basel). 2025;15(9):1088.
5. Yacoub M et al. J Sleep
Disord Ther. 2017;7(1):283.
6. Xu J et al. Chest. 2026.
7. Zhang X et al. Ann Med.
2026;58(1):2622175.
8. Tasali E et al. Circ Res.
2025;137(5):764-787.
9. Su K et al. Sleep Breath.
2025;29(6):323.
10. Guo S et al. BMC Psychiatry.
2025;25(1):790.
11. Young T. WMJ.
2009;108(5):246-249.
12. Gottlieb DJ et al. JAMA.
2020;323(14):1389-1400.
13. Dutta R
et al. Ann Am Thorac Soc.
2021;18(4):656-667.
14. Finnsson E et al. Front
Sleep. 2023;2:1188052.
15. Malhotra A et al. Curr Opin
Pulm Med. 2020;26(6):609-614.
16. American Academy of Sleep
Medicine. Sleep Apnea Screening Health Advisory. Accessed July 9, 2026.
17. Aurora RN et al. J Clin
Sleep Med. 2016;12(8):1185-1187.
18. Sateia M. Chest.
2014;146(5):1387-1394.
19. Rundo J. Cleve Clin J Med.
2019;86(9 Suppl 1):2-9.
20. Mazzotti DR et al. Am J
Respir Crit Care Med. 2019;200:493-506.
21. Kent DT et al. J Clin Sleep
Med. 2021;17:2499-2505.
22. Caples SM et al. Sleep. 2010;33(10):1396-1407.
23. Strollo
PJ Jr et al. N Engl J
Med. 2014;370(2):139-149.
24. Malhotra A et al. N Engl J
Med. 2024;391:1193-1205.
25. Strollo
PJ Jr et al. Am J Respir
Crit Care Med. 2026.
26. Eckert DJ. Drugs.
2026;86(2):143-159.
Content adapted for educational purposes from: “The New
Era of Obstructive Sleep Apnea (OSA) Care: From Underdiagnosis to an Evolving
Treatment Paradigm,” Reena Mehra, MD & Vani Potluri, MD, Pri-Med Institute,
supported by an educational grant from Apnimed Inc.
